CCA
REGN icon

Criterion Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Criterion Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$44.1K Hold
42
– – 0.03% 146
2024
Q3 		$44.1K Hold
42
– – 0.03% 146
2024
Q2 		$44.1K Hold
42
– – 0.03% 146
2024
Q1 		$40.4K Hold
42
– – 0.03% 150
2023
Q4 		$36.9K Buy
+42
New +$34.6K 0.03% 163

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Criterion Capital Advisors's REGN Position: Q4 2024 in Review

Criterion Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2024 at 42 shares worth $44.1K. The position accounts for 0.03% of the portfolio, ranked #146.

Criterion Capital Advisors first reported a position in REGN in Q4 2023 and has held it in 5 quarters since. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Criterion Capital Advisors held 42 shares of Regeneron Pharmaceuticals worth $44.1K as of Q4 2024.
  • Criterion Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q4 2024.
  • Regeneron Pharmaceuticals made up 0.03% of Criterion Capital Advisors's portfolio in Q4 2024, its #146 holding.
  • Criterion Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Criterion Capital Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.